Analyst Price Targets — BCRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 11:16 am | — | RBC Capital | $14.00 | $10.17 | TheFly | BioCryst price target raised to $14 from $13 at RBC Capital |
| June 30, 2026 11:33 am | — | Cantor Fitzgerald | $29.00 | $9.55 | TheFly | BioCryst price target raised to $29 from $27 at Cantor Fitzgerald |
| June 30, 2026 8:42 am | Maury Raycroft | Jefferies | $17.00 | $9.55 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies |
| November 5, 2025 10:41 am | Jonathan Wolleben | JMP Securities | $25.00 | $6.97 | TheFly | BioCryst price target lowered to $25 from $27 at Citizens JMP |
| November 4, 2025 10:07 am | — | Barclays | $9.00 | $6.86 | TheFly | BioCryst price target lowered to $9 from $11 at Barclays |
| October 14, 2025 7:51 pm | — | RBC Capital | $15.00 | $6.42 | TheFly | BioCryst weakness presents 'compelling' buying opportunity, says RBC |
| October 14, 2025 7:21 pm | Maury Raycroft | Jefferies | $15.00 | $6.42 | TheFly | BioCryst price target raised to $15 from $14 at Jefferies |
| October 1, 2025 12:36 pm | — | Evercore ISI | $8.00 | $7.24 | TheFly | BioCryst downgraded to In Line from Outperform at Evercore ISI |
| August 6, 2024 5:31 am | Gena Wang | Barclays | $7.00 | $7.51 | TheFly | BioCryst price target raised to $7 from $6 at Barclays |
| August 5, 2024 4:01 pm | Maury Raycroft | Jefferies | $11.00 | $7.51 | StreetInsider | BioCryst Pharma (BCRX) PT Raised to $11 at Jefferies |
Latest News for BCRX
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 115,805 shares of the biotechnology company's stock, valued at approximately $1,158,000. A
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE…
The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BCRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.